| Literature DB >> 33916166 |
Raquel Costa1,2, Daniela Azevedo2,3, Pedro Barata1,4, Raquel Soares1,2, Luís F Guido3, Daniel O Carvalho3.
Abstract
The Euterpe oleracea fruit (açaí) is a promising source of polyphenols with health-promoting properties. To our knowledge, few studies have focused on the influence of açaí phytochemicals on angiogenesis, with a significant impact on cancer. This study aimed at investigating the phytochemical profile of a purple açaí hydroethanolic extract (AHE) obtained from a commercial dietary powder supplement by high-performance liquid chromatography coupled to diode array detection and electrospray ionization mass spectrometry, and evaluate its in vitro effects on distinct angiogenic steps during vessel growth and on oxidative markers in human microvascular endothelial cells (HMEC-1). The phenolic profile of AHE revealed the presence of significant levels of anthocyanins, mainly cyanidin-3-O-rutinoside, and other flavonoids with promising health effects. The in vitro studies demonstrated that AHE exerts antiangiogenic activity with no cytotoxic effect. The AHE was able to decrease HMEC-1 migration and invasion potential, as well as to inhibit the formation of capillary-like structures. Additionally, AHE increased antioxidant defenses by upregulating superoxide dismutase and catalase enzymatic activities, accompanied by a reduction in the production of reactive oxygen species. These data bring new insights into the potential application of angiogenic inhibitors present in AHE on the development of novel therapeutic approaches for angiogenesis-dependent diseases.Entities:
Keywords: Euterpe oleracea; angiogenesis HPLC-DAD-ESI-MSn; anthocyanins; antioxidants; açaí; phenolic compounds
Mesh:
Substances:
Year: 2021 PMID: 33916166 PMCID: PMC8036632 DOI: 10.3390/molecules26072011
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chromatograms of açaí hydroethanolic extract (AHE) obtained at 280 nm (A), 340 (B) and 520 (C). Identified signals are presented in Table 1 and Table 2.
Retention time, maximum absorbance wavelengths and main fragments of anthocyanins tentatively assigned in AHE by HPLC-DAD-ESI-MSn, in positive ionization mode. The relative abundance of anthocyanins in AHE is presented as % of total peak area ± standard deviation (SD).
| Peak | Rt (Min) | λmax
| [M]+ ( | MS2 Fragment Ions ( | Proposed Identification | Peak Area |
|---|---|---|---|---|---|---|
| 4 | 30.6 | 280, 517 | 449 |
| Cyanidin-3- | 6.2 ± 0.3 |
| 5 | 34.8 | 280, 517 | 595 | 449, | Cyanidin-3- | 89.0 ± 0.3 |
| 6 | 38.7 | 280, 508 | 579 | 433, | Pelargonidin-3- | 2.3 ± 0.1 |
| 7 | 41.2 | 280, 517 | 609 | 463, | Peonidin 3- | 2.6 ± 0.5 |
Ions at bold represent base peaks.
Retention time, maximum absorbance wavelengths and main fragments of non-anthocyanin phenolic compounds tentatively assigned in AHE by HPLC-DAD-ESI-MSn, in negative ionization mode. The content of phenolic compounds was determined in mg/100 g dw and expressed as mean ± SD.
| Peak | Rt | λmax | [M-H]- | MS2 Fragments | MS3 fragments | Proposed Identification | Content |
|---|---|---|---|---|---|---|---|
|
| |||||||
| 1 | 18.2 | 260, 290 | 153 |
| - | Protocatechuic acid | 9.4 ± 0.9 a |
|
| |||||||
| 2 | 22.5 | 278 | 865 | 739, 713, | - | Proanthocyanidin trimer | 6.3 ± 0.1 b |
| 3 | 23.5 | 280 | 577 | 559, 451, | - | Proanthocyanidin dimer | 25.7 ± 0.4 b |
| Total | 32.0 ± 0.5 b | ||||||
|
| |||||||
| 8 | 48.9 | 277, 343 | 593 | 575, 503, | 383, | Apigenin-6,8-di- | 4.63 ± 0.2 c |
| 9 | 49.6 | 280, 340 | 579 | 561, 519, 489, | 399, | Luteolin-6- | 1.61 ± 0.01 c |
| 10 | 50.6 | 280, 340 | 579 | 561, 519, 489, | 399, | Luteolin-6- | 2.47 ± 0.02 c |
| 11 | 51.4 | 280, 340 | 579 | 561, 519, | 399, | Luteolin-6- | 1.40 ± 0.04 c |
| 12 | 54.4 | 280, 330 | 563 | 545, 503, | 383, | Apigenin-6- | 4.1 ± 0.1 c |
| 13 | 55.8 | 283, 340 | 449 | 287, | 241, | Taxifolin deoxyhexose | 33.1 ± 0.5 c |
| 14 | 56.9 | 270, 348 | 447 | 429, 357, | 327, | Luteolin-6- | 12.7 ± 0.5 c |
| 15 | 57.3 | 270, 346 | 447 | 429, 357, | 327, | Luteolin-8- | 5.4 ± 0.1 c |
| 16 | 59.2 | 270, 340 | 431 | 341, |
| Apigenin-8- | 4.79 ± 0.05 c |
| 17 | 62.7 | 290, 340 | 287 | 269, | 241, | Dihydrokaempferol | 9.6 ± 0.1 c |
| 18 | 64.1 | 274, 340 | 461 | 371, | 313, | Scoparin | 5.14 ± 0.02 c |
| 19 | 66.2 | 274, 335 | 689 | 519, | Luteolin- | 11.06 ± 0.05 c | |
| 20 | 68.3 | 274, 340 | 533 | 473, | 383, | Apigenin-6,8-di- | 2.39 ± 0.02 c |
| 21 | 71.6 | 275, 330 | 673 | Apigenin-di- | 11.6 ± 0.2 c | ||
| 22 | 75.4 | 280, 370 | 301 |
| Quercetin | 2.54 ± 0.01 c | |
| 23 | 77.2 | 260, 285, 350 | 285 | - | Luteolin | 2.30 ± 0.06 c | |
| 24 | 79.8 | 268, 350 | 315 |
| 283, | Isorhamnetin | 5.10 ± 0.04 c |
| 25 | 80.0 | 268, 343 | 329 |
|
| Tricin | 3.46 ± 0.08 c |
| Total | 123.3 ± 0.7 c | ||||||
Ions at bold represent base peaks; a identification and quantification performed using authentic standard; b expressed as catechin equivalents; c expressed as rutin equivalents.
Figure 2Cytotoxicity and antiproliferative capacity were assessed in HMEC-1 treated with different concentrations of AHE during 24 h. Metabolic activity was determined by MTS assay (A). AHE induces cytotoxicity at the highest concentration tested (75 mg/L), in comparison to control. Proliferation was evaluated by BrdU incorporation (B). There is an inhibition on HMEC-1 proliferation after treatment with AHE, in a dose-dependent manner. Results are expressed as % of control group. * p < 0.05 vs. control.
Figure 3The ability to impair HMEC-1 migration and invasion was performed after 16 h and 24 h treatment with AHE by injury assay (A,B) and matrigel-coated transwell assay (C,D), respectively. There is an abrogation in cell motility and the capacity to migrate to the wound area was reduced at a concentration of 25 mg/L (A). Dotted lines represent the wound healing area at the beginning of experiment (B). HMEC-1 invasive capacity through a matrigel membrane was reduced in a dose-dependent manner with significance for doses of 15 mg/L or higher (C). Representative images of invasive HMEC-1 under fluorescence microscope (D). Results are presented as % of control group mean ± SD. * p < 0.05 vs. control.
Figure 4Formation of capillary-like structures was quantified in HMEC-1 after treatment with AHE or control, by Matrigel assay. HMEC-1 reduces, dose-dependently, its ability to assemble into tubular structures in concentrations ranging from 10 to 25 mg/L (A). Representative images of endothelial assembly after 16 h of standard treatments. (B) Results are expressed as % of control group. * p < 0.05 vs. control.
Figure 5Evaluation of oxidative stress mediators after HMEC-1 treatment with AHE or control. Antioxidant SOD (A) and catalase (B) defenses were both augmented at concentrations of 20 and 25 mg/L, in comparison with control group, analyzed by enzymatic assays. Production of reactive oxygen species (ROS) was reduced dose-dependently, measured after incubation with fluorescence dies, with statistical significance at 15 mg/L or higher (C). Results are presented as % inhibition rate of SOD activity (A) nmol of catalase activity/min/mL (B) and units of fluorescence intensity for ROS production (C) * p < 0.05 vs. control.